$COSM
Cosmos Health Inc.

2024 Q4 Form 10-Q Financial Statement

#000147793224007222 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $12.41M $12.82M
YoY Change -3.22% 6.72%
Cost Of Revenue $11.20M $11.61M
YoY Change -3.49% 13.46%
Gross Profit $1.207M $1.215M
YoY Change -0.65% -31.9%
Gross Profit Margin 9.72% 9.47%
Selling, General & Admin $1.825M $2.731M
YoY Change -33.18% 89.77%
% of Gross Profit 151.2% 224.81%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $89.69K $124.9K
YoY Change -28.19% 50.11%
% of Gross Profit 7.43% 10.28%
Operating Expenses $3.447M $4.232M
YoY Change -18.56% 98.87%
Operating Profit -$2.240M -$3.017M
YoY Change -25.77% 776.84%
Interest Expense $181.4K $151.3K
YoY Change 19.93% -67.25%
% of Operating Profit
Other Income/Expense, Net $57.33K -$397.8K
YoY Change -114.41% -67.68%
Pretax Income -$2.183M -$3.415M
YoY Change -36.09% 116.87%
Income Tax $0.00 $65.87K
% Of Pretax Income
Net Earnings -$2.183M -$3.349M
YoY Change -34.83% 69.77%
Net Earnings / Revenue -17.59% -26.12%
Basic Earnings Per Share -$0.45 -$0.27
Diluted Earnings Per Share -$0.45 -$0.27
COMMON SHARES
Basic Shares Outstanding 23.35M shares 17.61M shares 10.62M shares
Diluted Shares Outstanding 18.42M shares 12.59M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.338M $2.378M
YoY Change 40.35% 637.71%
Cash & Equivalents $3.315M $2.361M
Short-Term Investments $22.81K $17.53K
Other Short-Term Assets $8.309M $8.736M
YoY Change -4.89% 25.63%
Inventory $4.885M $5.960M
Prepaid Expenses
Receivables $17.48M $25.59M
Other Receivables $937.7K $812.0K
Total Short-Term Assets $36.24M $46.49M
YoY Change -22.04% 19.66%
LONG-TERM ASSETS
Property, Plant & Equipment $10.58M $10.25M
YoY Change 3.18% 606.9%
Goodwill $49.70K $49.70K
YoY Change 0.0% 0.0%
Intangibles $7.697M $4.016M
YoY Change 91.67% 534.7%
Long-Term Investments
YoY Change
Other Assets $2.765M $2.600M
YoY Change 6.35% 139.22%
Total Long-Term Assets $28.28M $25.04M
YoY Change 12.95% 269.73%
TOTAL ASSETS
Total Short-Term Assets $36.24M $46.49M
Total Long-Term Assets $28.28M $25.04M
Total Assets $64.52M $71.53M
YoY Change -9.79% 56.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.63M $12.74M
YoY Change -0.87% 8.62%
Accrued Expenses $185.6K $82.50K
YoY Change 124.92% -95.89%
Deferred Revenue
YoY Change
Short-Term Debt $6.022M $5.378M
YoY Change 11.97% -36.65%
Long-Term Debt Due $1.641M $1.188M
YoY Change 38.13% -90.48%
Total Short-Term Liabilities $25.21M $22.59M
YoY Change 11.63% -38.8%
LONG-TERM LIABILITIES
Long-Term Debt $2.651M $3.422M
YoY Change -22.53% 1138.98%
Other Long-Term Liabilities $1.213M $321.4K
YoY Change 277.31% -85.12%
Total Long-Term Liabilities $1.213M $321.4K
YoY Change 277.31% 16.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.21M $22.59M
Total Long-Term Liabilities $1.213M $321.4K
Total Liabilities $29.54M $26.96M
YoY Change 9.59% -33.38%
SHAREHOLDERS EQUITY
Retained Earnings -$104.5M -$71.04M
YoY Change 47.07% 30.72%
Common Stock $23.35K $13.07K
YoY Change 78.64% -50.43%
Preferred Stock
YoY Change
Treasury Stock (at cost) $917.0K
YoY Change 12.28%
Treasury Stock Shares
Shareholders Equity $34.98M $44.20M
YoY Change
Total Liabilities & Shareholders Equity $64.52M $71.53M
YoY Change -9.79% 56.78%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.183M -$3.349M
YoY Change -34.83% 69.77%
Depreciation, Depletion And Amortization $89.69K $124.9K
YoY Change -28.19% 50.11%
Cash From Operating Activities $739.8K -$4.528M
YoY Change -116.34% 196.19%
INVESTING ACTIVITIES
Capital Expenditures $228.8K $484.7K
YoY Change -52.8% 16218.52%
Acquisitions
YoY Change
Other Investing Activities $193.3K -$1.475M
YoY Change -113.11% -1768.3%
Cash From Investing Activities -$35.43K -$1.949M
YoY Change -98.18% -2233.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.680M 6.342M
YoY Change -57.74% 531.25%
NET CHANGE
Cash From Operating Activities 739.8K -4.528M
Cash From Investing Activities -35.43K -1.949M
Cash From Financing Activities 2.680M 6.342M
Net Change In Cash 3.384M -135.2K
YoY Change -2602.48% -68.74%
FREE CASH FLOW
Cash From Operating Activities $739.8K -$4.528M
Capital Expenditures $228.8K $484.7K
Free Cash Flow $511.0K -$5.012M
YoY Change -110.19% 227.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1377286 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1048126 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10575928 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10455499 usd
CY2024Q3 us-gaap Other Finite Lived Intangible Assets Gross
OtherFiniteLivedIntangibleAssetsGross
8764468 usd
CY2023Q4 us-gaap Other Finite Lived Intangible Assets Gross
OtherFiniteLivedIntangibleAssetsGross
8029357 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7697064 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7634486 usd
CY2024Q3 us-gaap Goodwill
Goodwill
49697 usd
CY2023Q4 us-gaap Goodwill
Goodwill
49697 usd
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
7746761 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
7684183 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
208530 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
834846 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
834846 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
783423 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
3846582 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7341864 usd
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
3950000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
0 usd
us-gaap Allowance For Loan And Lease Losses Write Offs
AllowanceForLoanAndLeaseLossesWriteOffs
250971 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
-31286 usd
CY2024Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
322576 usd
CY2023Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
187512 usd
CY2024Q3 us-gaap Depreciation
Depreciation
89694 usd
CY2023Q2 us-gaap Depreciation
Depreciation
124910 usd
us-gaap Depreciation
Depreciation
306126 usd
us-gaap Depreciation
Depreciation
237479 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
196183 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
88168 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
579556 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
138438 usd
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606, <em>Revenue from Contracts with Customers</em> (“ASC 606”), the Company uses a five-step model for recognizing revenue by applying the following steps: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of the Contract: The Company identifies a contract with a customer when it enters into an agreement that creates enforceable rights and obligations.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Identification of Performance Obligations: The Company identifies distinct performance obligations within each contract, which represent promises to transfer goods or services to the customer.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Determination of Transaction Price: The Company determines the transaction price, which represents the amount of consideration to which it expects to be entitled in exchange for transferring promised goods or services to the customer, excluding any amounts collected on behalf of third parties.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Allocation of Transaction Price: The Company allocates the transaction price to each distinct performance obligation based on its standalone selling price. If the standalone selling price is not observable, the Company estimates it using an appropriate method.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Recognition of Revenue: Revenue is recognized when (or as) the Company satisfies a performance obligation by transferring a promised good or service to the customer. This typically occurs at a point in time or over time, depending on the nature of the performance obligation.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Wholesale revenue and sales of own branded nutraceutical and pharmaceutical products</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has contracts or signed partnership forms (usual in the wholesale sector of the pharma industry) with its customers, stipulating enforceable rights and obligations. The Company is responsible for transferring the goods to the customer’s location, which represents its sole performance obligation. Thus, the transaction price, which is predetermined in most of the products sold, is exclusively allocated to this performance obligation. Revenue is recognized at a single point in time, which is upon issuance of the corresponding sales invoice. The Company has assessed the impact of the items invoiced but not delivered to the customer’s location as of December 31, 2023 and September 30, 2024, and deemed that it had no material effect. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Pharma manufacturing</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has active contracts with its customers, stipulating enforceable rights and obligations. The Company is responsible for the manufacturing and the packaging of specific products assigned by its customers, which represents its performance obligations to which the Company allocates the transaction price determined. The customers are responsible for providing the raw materials to the Company. Revenue is recognized over a period of time, which is during the production and packaging period of the respective products. As of September 30, 2024, there were no products or batches of products for which the production or packaging phase was in progress. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Medihelm SA </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassesses each reporting period. Through this assessment, the Company applied the “expected value” model under ASC 606-10-32-5 and had applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model, the Company had deferred an amount of $397,000 and recorded it against the sales to Medihelm for the twelve months ended December 31, 2023. However, the Company assessed once more the trading relationship with Medihelm SA at year end and since no significant receipts had taken place up to the issuance of the report, the Company recorded an allowance for the total receivable amount not received up to the issuance date. More specifically a cumulative reserve of $12,655,615 was applied, leaving a receivable of $532,704 due from Medihelm SA, as of December 31, 2023. The Company does not consider that new sales to Medihelm SA or sales to any other customer include a variable component as of September 30, 2024 and has limited such sales to the minimum required.</p>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17724305 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346071 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
13432507 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
6124412 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
13432507 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
6124412 shares
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11953214 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11503625 usd
CY2021Q4 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
4849221 usd
CY2021Q4 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.055 pure
CY2023 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
389867 usd
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
411858 usd
CY2023Q4 us-gaap Nontrade Receivables
NontradeReceivables
3509200 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-65873 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
901488 shares
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
648893 usd
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
5989425 usd
CY2023Q4 us-gaap Line Of Credit
LineOfCredit
6630273 usd
us-gaap Line Of Credit Facility Description
LineOfCreditFacilityDescription
The Company has three lines of credit with the National Bank of Greece, which are renewed annually. The three lines have interest rates of 6.00% (the "National Bank LOC"), 3.6% (the "COSME 2 Facility"), and 3.6% plus the six-month Euribor rate and any contributions currently in force by law on certain lines of credit (the "COSME 1 Facility")
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1717738 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
420633 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
353961 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
153291 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
4267972 usd
CY2022Q1 us-gaap Debt Current
DebtCurrent
3950000 usd
CY2021Q3 us-gaap Debt Current
DebtCurrent
578850 usd
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P4Y29D
us-gaap Acquired Finite Lived Intangible Asset Weighted Average Period Before Renewal Or Extension
AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension
P1Y2M8D
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
644779 usd
us-gaap Proceeds From Customers For Progress Payments
ProceedsFromCustomersForProgressPayments
451575 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109636 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
326525 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001474167
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Trading Symbol
TradingSymbol
COSM
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
86497 shares
us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 abcd Common Stocks Shares Issued
CommonStocksSharesIssued
1487000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54436
dei Entity Registrant Name
EntityRegistrantName
COSMOS HEALTH INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0611758
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Agiou Georgiou Str
dei Entity Address Address Line2
EntityAddressAddressLine2
Pilea
dei Entity Address City Or Town
EntityAddressCityOrTown
Thessaloniki
dei Entity Address Country
EntityAddressCountry
GR
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55438
dei City Area Code
CityAreaCode
312
dei Local Phone Number
LocalPhoneNumber
536-3102
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23346049 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3314845 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3833195 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17484240 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19759254 usd
CY2024Q3 abcd Amount Accounts Receivable Related Parties Current
AmountAccountsReceivableRelatedPartiesCurrent
1285743 usd
CY2023Q4 abcd Amount Accounts Receivable Related Parties Current
AmountAccountsReceivableRelatedPartiesCurrent
1099098 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
22808 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20075 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
4885015 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
4789054 usd
CY2024Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
491897 usd
CY2023Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
411858 usd
CY2024Q3 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
445800 usd
CY2023Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
442480 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1914881 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1811911 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6393642 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4440855 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
36238871 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
36607780 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10575928 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10455499 usd
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
7746761 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
7684183 usd
CY2024Q3 abcd Loans Receivable Noncurrent
LoansReceivableNoncurrent
3225879 usd
CY2023Q4 abcd Loans Receivable Noncurrent
LoansReceivableNoncurrent
3509200 usd
CY2024Q3 abcd Loans Receivable Related Party Noncurrent
LoansReceivableRelatedPartyNoncurrent
3234604 usd
CY2023Q4 abcd Loans Receivable Related Party Noncurrent
LoansReceivableRelatedPartyNoncurrent
3539840 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
710711 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1131552 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
22343 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
28790 usd
CY2024Q3 abcd Advances For Buildings Acquisition
AdvancesForBuildingsAcquisition
2000020 usd
CY2023Q4 abcd Advances For Buildings Acquisition
AdvancesForBuildingsAcquisition
2000020 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
764865 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
1057947 usd
CY2024Q3 us-gaap Assets
Assets
64519982 usd
CY2023Q4 us-gaap Assets
Assets
66014811 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11605255 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11911978 usd
CY2024Q3 abcd Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
1027327 usd
CY2023Q4 abcd Accounts Payable And Accrued Expenses Related Parties Current
AccountsPayableAndAccruedExpensesRelatedPartiesCurrent
231564 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
185561 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
166348 usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5989425 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
6630273 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1622349 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1570886 usd
CY2024Q3 abcd Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
11368 usd
CY2023Q4 abcd Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
11283 usd
CY2024Q3 abcd Loans Payable Related Parties Current
LoansPayableRelatedPartiesCurrent
21158 usd
CY2023Q4 abcd Loans Payable Related Parties Current
LoansPayableRelatedPartiesCurrent
13257 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
241422 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
285563 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
18888 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
27222 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4488465 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3474096 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25211218 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24322470 usd
CY2024Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
0 usd
CY2023Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
0 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
2645623 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3035341 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
468157 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
844866 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5845 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5261 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1212540 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1763845 usd
CY2024Q3 us-gaap Liabilities
Liabilities
29543383 usd
CY2023Q4 us-gaap Liabilities
Liabilities
29971783 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23346023 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15982472 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23259526 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15895975 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
23346 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
15983 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140797456 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129008301 usd
CY2024Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
20 usd
CY2023Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
20 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
86497 shares
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
917159 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
917159 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104479192 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91644233 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-447832 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-419844 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34976599 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
36043028 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64519982 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66014811 usd
CY2024Q3 us-gaap Revenues
Revenues
12411048 usd
CY2023Q3 us-gaap Revenues
Revenues
12823797 usd
us-gaap Revenues
Revenues
40202238 usd
us-gaap Revenues
Revenues
37537003 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11204186 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11609039 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36894502 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
34418334 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1206862 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1214758 usd
us-gaap Gross Profit
GrossProfit
3307736 usd
us-gaap Gross Profit
GrossProfit
3118669 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1782957 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2573414 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4591620 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6662579 usd
CY2024Q3 us-gaap Salaries And Wages
SalariesAndWages
1317782 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
1252680 usd
us-gaap Salaries And Wages
SalariesAndWages
4030823 usd
us-gaap Salaries And Wages
SalariesAndWages
3279803 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
41848 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
157435 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
326291 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
942759 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
304139 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
248530 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
937000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
478466 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3446726 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4232059 usd
us-gaap Operating Expenses
OperatingExpenses
9885734 usd
us-gaap Operating Expenses
OperatingExpenses
11363607 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2239864 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3017301 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6577998 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8244938 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1921 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14404 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
160598 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14330 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
181429 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
151274 usd
us-gaap Interest Expense
InterestExpense
692547 usd
us-gaap Interest Expense
InterestExpense
529782 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
101236 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
110596 usd
us-gaap Interest Income Other
InterestIncomeOther
309031 usd
us-gaap Interest Income Other
InterestIncomeOther
555281 usd
CY2024Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
428 usd
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
-1093 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
2518 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
2876 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
706 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1911476 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3384 usd
CY2024Q3 abcd Bargain Purchase Gain
BargainPurchaseGain
0 usd
CY2023Q3 abcd Bargain Purchase Gain
BargainPurchaseGain
0 usd
abcd Bargain Purchase Gain
BargainPurchaseGain
0 usd
abcd Bargain Purchase Gain
BargainPurchaseGain
1633842 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
139016 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-371115 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
158463 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-108406 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
57330 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-397776 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-61937 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3454341 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2182534 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3415077 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6639935 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4790597 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-65873 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2182534 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349204 usd
us-gaap Net Income Loss
NetIncomeLoss
-6639935 usd
us-gaap Net Income Loss
NetIncomeLoss
-4790597 usd
CY2024Q3 us-gaap Investment Income Dividend
InvestmentIncomeDividend
6185231 usd
CY2023Q3 us-gaap Investment Income Dividend
InvestmentIncomeDividend
0 usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
6185231 usd
CY2024Q3 abcd Deemed Dividend On Downround Of Warrants
DeemedDividendOnDownroundOfWarrants
0 usd
CY2023Q3 abcd Deemed Dividend On Downround Of Warrants
DeemedDividendOnDownroundOfWarrants
-15053 usd
abcd Deemed Dividend On Downround Of Warrants
DeemedDividendOnDownroundOfWarrants
0 usd
abcd Deemed Dividend On Downround Of Warrants
DeemedDividendOnDownroundOfWarrants
-15053 usd
CY2024Q3 abcd Deemed Dividend On Warrant Exchange Modification
DeemedDividendOnWarrantExchangeModification
-9793 usd
CY2023Q3 abcd Deemed Dividend On Warrant Exchange Modification
DeemedDividendOnWarrantExchangeModification
0 usd
abcd Deemed Dividend On Warrant Exchange Modification
DeemedDividendOnWarrantExchangeModification
-9793 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8377558 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3364257 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12834959 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4805650 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
747879 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-890645 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27988 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-470994 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7629679 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4254902 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12862947 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5276644 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18418287 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12585479 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17724305 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346071 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18418287 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12585479 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17724305 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346071 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
39284295 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
336463 usd
CY2023Q1 abcd Proceeds From Sale Of Common Stock
ProceedsFromSaleOfCommonStock
4750000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96888 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-459863 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
44007783 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83188 usd
CY2023Q2 abcd Shares Issued For Purchase Of Customer Base Amount
SharesIssuedForPurchaseOfCustomerBaseAmount
316081 usd
CY2023Q2 abcd Shares Issued For Purchase Of Cana Amount
SharesIssuedForPurchaseOfCanaAmount
138667 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
104869 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-981530 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43669058 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-890645 usd
CY2023Q3 abcd Proceeds From Sale Of Common Stock Net Of Financing Fees Amount
ProceedsFromSaleOfCommonStockNetOfFinancingFeesAmount
4757146 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
100251 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
109636 usd
CY2023Q3 abcd Deemed Dividend
DeemedDividend
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349204 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
44195740 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
36043028 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-599276 usd
CY2024Q1 abcd Proceeds From Sale Of Common Stock Net Of Financing Fees Of Amount
ProceedsFromSaleOfCommonStockNetOfFinancingFeesOfAmount
629426 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108297 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
231897 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1866690 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
34546682 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-176591 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108444 usd
CY2023Q3 abcd Deemed Dividend
DeemedDividend
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
231750 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2590711 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
32119574 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
747879 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
158061 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
264750 usd
CY2024Q3 abcd Proceeds From Exercise Of Warrants Net Of Financing Fees Amount
ProceedsFromExerciseOfWarrantsNetOfFinancingFeesAmount
3868869 usd
CY2024Q1 abcd Shares Issued Pursuant To Warrant Exchange Agreement Amount
SharesIssuedPursuantToWarrantExchangeAgreementAmount
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2182534 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34976599 usd
us-gaap Profit Loss
ProfitLoss
-6639935 usd
us-gaap Profit Loss
ProfitLoss
-4790597 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
914493 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
375918 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22507 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
102549 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-31287 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
836300 usd
abcd Provision For Extraordinary Tax Charges
ProvisionForExtraordinaryTaxCharges
0 usd
abcd Provision For Extraordinary Tax Charges
ProvisionForExtraordinaryTaxCharges
579387 usd
abcd Shares Issued For Cash
SharesIssuedForCash
96888 shares
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
235659 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
178893 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1765 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
20629 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1103200 usd
us-gaap Share Based Compensation
ShareBasedCompensation
214505 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1923 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1911476 usd
abcd Gain Loss On Bargain Purchase
GainLossOnBargainPurchase
0 usd
abcd Gain Loss On Bargain Purchase
GainLossOnBargainPurchase
1633842 usd
abcd Change In Fair Value Of The Derivative Liability
ChangeInFairValueOfTheDerivativeLiability
0 usd
abcd Change In Fair Value Of The Derivative Liability
ChangeInFairValueOfTheDerivativeLiability
3384 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
2518 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
2876 usd
us-gaap Other Income
OtherIncome
0 usd
us-gaap Other Income
OtherIncome
928 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2392104 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1960236 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
176512 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
416814 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
46301 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2299829 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
283932 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1856642 usd
abcd Increase Decrease In Prepaid Expenses And Other Current Assets Related Party
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty
1873513 usd
abcd Increase Decrease In Prepaid Expenses And Other Current Assets Related Party
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParty
2312324 usd
abcd Proceeds From Loan Receivable Related Party
ProceedsFromLoanReceivableRelatedParty
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-437391 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
206746 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
795471 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-112233 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
17531 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-194361 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-234834 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179081 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
0 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
307357 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
910885 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-783174 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-550606 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1047178 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3883215 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16587726 usd
us-gaap Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
550565 usd
us-gaap Proceeds From Sale Of Loans Receivable
ProceedsFromSaleOfLoansReceivable
609455 usd
abcd Cash Paid For The Acquisition Of Cana
CashPaidForTheAcquisitionOfCana
0 usd
abcd Cash Paid For The Acquisition Of Cana
CashPaidForTheAcquisitionOfCana
5230593 usd
abcd Payment For Loan Receivable Related Party
PaymentForLoanReceivableRelatedParty
0 usd
abcd Payment For Loan Receivable Related Party
PaymentForLoanReceivableRelatedParty
168469 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
1999 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 usd
abcd Payment For Advances For Buildings Acquisition
PaymentForAdvancesForBuildingsAcquisition
0 usd
abcd Payment For Advances For Buildings Acquisition
PaymentForAdvancesForBuildingsAcquisition
1665000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2678167 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
345593 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1266490 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
206971 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10399264 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
100000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
814267 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1494867 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
434797 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1059300 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
7609 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
15218 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
19504594 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
14569517 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
18831043 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14218787 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
649039 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9950037 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4240977 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26408 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
118847 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
100251 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
391575 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
442892 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3426621 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8401750 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-268727 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
196161 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-518350 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18389079 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3833195 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20749683 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3314845 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2360604 usd
us-gaap Interest Paid Net
InterestPaidNet
198194 usd
us-gaap Interest Paid Net
InterestPaidNet
317449 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
abcd Common Shares Issued For Acquisition Of Customer Base
CommonSharesIssuedForAcquisitionOfCustomerBase
316081 usd
abcd Common Shares Issued For Acquisition Of Cana
CommonSharesIssuedForAcquisitionOfCana
138667 usd
abcd Closing Of Acquisition Of Cloudscreen
ClosingOfAcquisitionOfCloudscreen
637080 usd
abcd Closing Of Acquisition Of Cloudscreen
ClosingOfAcquisitionOfCloudscreen
0 usd
abcd Deemed Dividend Upon Warrant Exchange
DeemedDividendUponWarrantExchange
6195024 usd
abcd Deemed Dividend Upon Warrant Exchange
DeemedDividendUponWarrantExchange
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
372303 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
abcd Common Stock Issued To Consultants
CommonStockIssuedToConsultants
727570 usd
abcd Common Stock Issued To Consultants
CommonStockIssuedToConsultants
0 usd
us-gaap Profit Loss
ProfitLoss
-6639935 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104479192 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
34976599 usd
abcd Description Of The Warrants And Reduced The Exercise Price
DescriptionOfTheWarrantsAndReducedTheExercisePrice
which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977
abcd Allowance For Doubtful Accounts
AllowanceForDoubtfulAccounts
19905776 usd
CY2023 abcd Allowance For Doubtful Accounts
AllowanceForDoubtfulAccounts
19686091 usd
abcd Changes In Allowance For Doubtful Accounts Beginning Balance
ChangesInAllowanceForDoubtfulAccountsBeginningBalance
19686091 usd
abcd Changes In Allowance For Doubtful Accounts Ending Balance
ChangesInAllowanceForDoubtfulAccountsEndingBalance
19905776 usd
CY2018Q4 us-gaap Goodwill
Goodwill
49697 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
397000 usd
CY2024Q3 abcd Foreign Accounts
ForeignAccounts
12655615 usd
CY2023Q4 abcd Foreign Accounts
ForeignAccounts
532704 usd
CY2024Q3 abcd Long Term Liabilities
LongTermLiabilities
395698 usd
CY2023Q4 abcd Long Term Liabilities
LongTermLiabilities
408665 usd
abcd Weighted Average Number Of Common And Equivalent Shares Outstanding Diluted
WeightedAverageNumberOfCommonAndEquivalentSharesOutstandingDiluted
17724305 shares
abcd Weighted Average Number Of Common And Equivalent Shares Outstanding Diluted
WeightedAverageNumberOfCommonAndEquivalentSharesOutstandingDiluted
11346071 shares
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
833637 usd
CY2021Q4 abcd Threshold Period Past Due For Writeoffs Of Financing Receivable
ThresholdPeriodPastDueForWriteoffsOfFinancingReceivable
P360D
CY2021Q4 abcd Decription Of Loan Payment
DecriptionOfLoanPayment
the Company is to receive 120 equal payments over the term of the loan
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
249552 usd
abcd Interest Payments
InterestPayments
119411 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q3 abcd Common Stocks Shares Issued
CommonStocksSharesIssued
17834023 shares
CY2023Q4 abcd Common Stocks Shares Issued
CommonStocksSharesIssued
15982472 shares
CY2024Q3 abcd Common Stocks Shares Outstanding
CommonStocksSharesOutstanding
21346023 shares
CY2023Q4 abcd Common Stocks Shares Outstanding
CommonStocksSharesOutstanding
15895975 shares
CY2023Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3533741 usd
CY2023Q4 abcd Shares Held In Escrow
SharesHeldInEscrow
950063 shares
CY2024Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4240977 usd
CY2024Q3 abcd Common Stocks Shares Issued
CommonStocksSharesIssued
2332000 shares
CY2024Q3 abcd Shares Held In Escrow
SharesHeldInEscrow
2532126 shares
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1622349 usd
CY2024Q3 abcd Less Notes Payable Current Portion
LessNotesPayableCurrentPortion
-1622349 usd
CY2024Q3 abcd Notes Payable Long Term Portion
NotesPayableLongTermPortion
2645623 usd
abcd Trade Finance Facility Agreement Interest Rate Description
TradeFinanceFacilityAgreementInterestRateDescription
one-month Euribor (3.90% as of December 31, 2023), and 6% plus one-month LIBOR (fully paid as of December 31, 2023), respectively
abcd Five Quarterly Installments
FiveQuarterlyInstallments
54600 shares
abcd Final Repayment Shares
FinalRepaymentShares
1965600 shares
abcd Non Cash Interest Expenses
NonCashInterestExpenses
221060 usd
CY2022 abcd Non Cash Interest Expenses
NonCashInterestExpenses
200000 usd
abcd Stock Issued For Debt Obligation
StockIssuedForDebtObligation
420471 shares
abcd Operating Lease Term Of Agreements
OperatingLeaseTermOfAgreements
The Company has various operating and finance lease agreements with terms up to 10 years
abcd Operating Lease Weighted Average Discount Rate
OperatingLeaseWeightedAverageDiscountRate
0.0674 pure
abcd Finance Lease Weighted Average Discount Rate
FinanceLeaseWeightedAverageDiscountRate
0.0674 pure
CY2024Q3 abcd Operating Lease Cash Flows Used In Finance Lease
OperatingLeaseCashFlowsUsedInFinanceLease
9765 usd
abcd Operating Lease Cash Flows Used In Finance Lease
OperatingLeaseCashFlowsUsedInFinanceLease
41094 usd
CY2023Q3 abcd Operating Lease Cash Flows Used In Finance Lease
OperatingLeaseCashFlowsUsedInFinanceLease
27118 usd
abcd Operating Lease Cash Flows Used In Finance Lease
OperatingLeaseCashFlowsUsedInFinanceLease
118847 usd
CY2024Q3 abcd Finance Lease Amortization Expense
FinanceLeaseAmortizationExpense
7589 usd
abcd Finance Lease Amortization Expense
FinanceLeaseAmortizationExpense
35452 usd
CY2023Q3 abcd Finance Lease Amortization Expense
FinanceLeaseAmortizationExpense
22507 usd
abcd Finance Lease Amortization Expense
FinanceLeaseAmortizationExpense
102549 usd
abcd Tax Liabilities Payable
TaxLiabilitiesPayable
1812919 usd
abcd Payroll Tax Related Current Liabilities
PayrollTaxRelatedCurrentLiabilities
1799431 usd
abcd Provision For Staff Leaving Compensation
ProvisionForStaffLeavingCompensation
411732 usd
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
407725 usd
abcd Payment Tax
PaymentTax
99644 usd
CY2021Q3 abcd Advisory Description
AdvisoryDescription
As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023
abcd Complementary Compensation Shares
ComplementaryCompensationShares
440000 shares
abcd Additional Stock Consideration
AdditionalStockConsideration
264000 usd
abcd Discription Of Incentive Stock Awards
DiscriptionOfIncentiveStockAwards
The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024
CY2023Q2 abcd Awarded Shares
AwardedShares
185000 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109636 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
214505 usd
CY2024Q3 us-gaap Revenues
Revenues
12411048 usd
CY2023Q3 us-gaap Revenues
Revenues
12823797 usd
us-gaap Revenues
Revenues
40202238 usd
us-gaap Revenues
Revenues
37537003 usd

Files In Submission

Name View Source Status
0001477932-24-007222-index-headers.html Edgar Link pending
0001477932-24-007222-index.html Edgar Link pending
0001477932-24-007222.txt Edgar Link pending
0001477932-24-007222-xbrl.zip Edgar Link pending
abcd-20240930.xsd Edgar Link pending
cosm_10q.htm Edgar Link pending
cosm_ex311.htm Edgar Link pending
cosm_ex312.htm Edgar Link pending
cosm_ex321.htm Edgar Link pending
cosm_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
abcd-20240930_lab.xml Edgar Link unprocessable
abcd-20240930_def.xml Edgar Link unprocessable
abcd-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cosm_10q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abcd-20240930_cal.xml Edgar Link unprocessable